Loading
Latest filing published 25 May 2022 for Kempharm, INC, €8,151. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
All filings by Travis C. Mickle on record concern Zevra Therapeutics, Inc., in the capacity of chief executive. We count 5 filings; the first trade dates from 14 June 2021 and the latest from 25 May 2022.
Every open-market trade on record is a purchase: 4 purchases worth €80k, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2022: 1 purchase and no sales on the market.
A typical purchase (the median) is worth €17k. On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.
Most recently, on 25 May 2022, the filings show an open-market purchase worth €8,151 in Zevra Therapeutics, Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations